Author

Corinna Lanzarotti

Observed name: C. Lanzarotti

Institution: Helsinn (Switzerland)

Observed institution: Helsinn (Switzerland)

OpenAlex ID: A5091163941

A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC)

2017 · L. Zhang, S. Lu, et al. · Annals of Oncology · 114

Netupitant PET imaging and ADME studies in humans

2013 · Tulla Spinelli, Selma Calcagnile, et al. · The Journal of Clinical Pharmacology · 56

Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone

2013 · Corinna Lanzarotti, Giorgia Rossi · Supportive Care in Cancer · 42

Effect of netupitant, a highly selective NK1 receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives

2013 · Selma Calcagnile, Corinna Lanzarotti, et al. · Supportive Care in Cancer · 32

Efficacy of NEPA, a fixed antiemetic combination of netupitant and palonosetron, vs a 3‐day aprepitant regimen for prevention of chemotherapy‐induced nausea and vomiting (CINV) in Chinese patients receiving highly emetogenic chemotherapy (HEC) in a randomized Phase 3 study

2020 · Jianhua Chang, Gongyan Chen, et al. · Cancer Medicine · 22

Drug–drug interaction profile of components of a fixed combination of netupitant and palonosetron: Review of clinical data

2015 · James J Natale, Tulla Spinelli, et al. · Journal of Oncology Pharmacy Practice · 22

Evaluation of the effect of food and age on the pharmacokinetics of oral netupitant and palonosetron in healthy subjects: A randomized, open‐label, crossover phase 1 study

2015 · Selma Calcagnile, Corinna Lanzarotti, et al. · Clinical Pharmacology in Drug Development · 11

Pharmacokinetics and safety evaluation of oral Palonosetron in Chinese healthy volunteers: A phase 1, open-label, randomized, cross-over study

2021 · Rui Chen, Hongyun Wang, et al. · European Journal of Pharmaceutical Sciences · 4

Evaluation of daily breakthrough chemotherapy-induced nausea and vomiting (CINV) rates in a phase III study of NEPA versus an aprepitant (APR)/granisetron (GRAN) regimen.

2017 · Eric Roeland, Gary Binder, et al. · Journal of Clinical Oncology · 4

Pharmacokinetic (PK) study of a single oral dose of NEPA in Chinese healthy volunteers (HVs)

2017 · R. Chen, S. Chessari, et al. · Annals of Oncology · 2

Phase III study of NEPA, a fixed combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV).

2017 · Li Zhang, Shun Lu, et al. · Journal of Clinical Oncology · 2

A phase 1 pharmacokinetic study of oral NEPA, the fixed combination of netupitant and palonosetron, in Chinese healthy volunteers

2021 · Rui Chen, Hongyun Wang, et al. · Cancer Chemotherapy and Pharmacology

MA 08.02 Efficacy of Single-Dose NEPA versus 3-Day Aprepitant Regimen for Prevention of CINV: A Phase 3 Lung Cancer Subset Analysis

2017 · S. Lu, L. Zhang, et al. · Journal of Thoracic Oncology

Phase 3 efficacy results of a single dose of NEPA, a fixed combination of netupitant and palonosetron, versus a 3-day regimen of aprepitant/granisetron (APR/GRAN) for prevention of chemotherapy-induced nausea and vomiting (CINV) in Chinese patients

2017 · L. Zhang, S. Lu, et al. · Annals of Oncology

Quality of life (QOL) evaluation of patients in a phase 3 study comparing NEPA with an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV)

2017 · L. Zhang, S. Lu, et al. · Annals of Oncology

Works count: 15

Citation count: 311

H-index: 7

I10-index: 7